A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC)
Conditions: HPV16+ Squamous Cell Carcinoma Interventions: Drug: HB-200; Other: Placebo Sponsors: Memorial Sloan Kettering Cancer Center; Hookipa Biotech GmbH; Naveris Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Carcinoma | Head and Neck Cancer | HNSCC | Human Papillomavirus (HPV) | Research | Skin Cancer | Squamous Cell Carcinoma | Study